These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830 [TBL] [Abstract][Full Text] [Related]
4. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Lath R; Chacko G; Chandy MJ Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918 [TBL] [Abstract][Full Text] [Related]
6. CD147 expression in pituitary adenomas and its significance for clinical outcome. Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119 [TBL] [Abstract][Full Text] [Related]
7. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A; Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794 [TBL] [Abstract][Full Text] [Related]
8. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Gejman R; Swearingen B; Hedley-Whyte ET Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942 [TBL] [Abstract][Full Text] [Related]
9. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]
10. A classification tree approach for pituitary adenomas. Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review. Sahli R; Christ ER; Seiler R; Kappeler A; Vajtai I Pathol Res Pract; 2006; 202(6):457-64. PubMed ID: 16497445 [TBL] [Abstract][Full Text] [Related]
13. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025 [TBL] [Abstract][Full Text] [Related]
14. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500 [TBL] [Abstract][Full Text] [Related]